Skip to main content
PMC home page
Sexually Transmitted Infections logoLink to Sexually Transmitted Infections
. 1998 Apr;74(2):110–115. doi: 10.1136/sti.74.2.110

Hepatitis B virus infection in patients attending a genitourinary medicine clinic: risk factors and vaccine coverage

R J Gilson, A de Ruiter, J Waite, E Ross, C Loveday, D R Howell, R S Tedder, I V Weller
PMCID: PMC1758098  PMID: 9634322

Abstract

BACKGROUND: The hepatitis B virus (HBV) immunisation policy in the United Kingdom includes offering vaccines selectively to those at risk by sexual contact. Among genitourinary medicine (GUM) clinic attenders, homosexual men are offered vaccine, but estimates of the vaccine uptake are required to monitor policy and estimate the possible impact on transmission; heterosexuals are not routinely offered vaccine, but this policy might change if the prevalence was found to be high. OBJECTIVE: To determine the prevalence of HBV infection and vaccine uptake among patients attending a GUM clinic. METHODS: HBV seroprevalence determined by unlinked anonymous testing of consecutive blood samples sent for syphilis serology. Demographic and risk factor data and history of HBV immunization extracted from clinic notes before unlinking. Prevalence data were compared with a population of first time blood donors from the same area. SETTING: Open access GUM clinic in central London. RESULTS: Samples were obtained and tested from 441 homosexual and 527 heterosexual men and from 821 women over a 4 month period in 1990. After exclusion of injecting drug users and their sexual partners (n = 30) and HBV carriers attending for follow up (n = 12), the prevalence of antibody to HBV core (anti-HBc) was 38.7% in homosexual men, 5.9% in heterosexual men, and 3.5% in women (50.0%, 6.0%, 3.7% respectively if previous vaccinees were also excluded). The prevalence of HBV surface antigen positivity was 4.2%, 0.60%, and 0.39% respectively after exclusion of vaccinees (chi(2) p < 0.001 for homosexual men versus others). The prevalence of the anti-HBc in first time blood donors was 1.1% (8/749). Among male GUM clinic attenders, the prevalence of anti-HBc was higher in those of non-UK origin or place of birth and/or non-white ethnicity (odds ratios 2.87, 95% CI 1.57-5.24 and 8.06, CI 3.39-19.1, in homosexuals and heterosexuals respectively). In homosexual men anti-HBc prevalence increased with age (OR 1.05, CI 1.02-1.07 for each year) and lifetime number of STDs (OR 6.36, CI 3.77-10.8 for > or = 2 versus < 2) and in clinic reattenders compared with new patients (OR 5.42, 95% CI 3.32-9.16). Among heterosexuals, age was associated with anti-HBc prevalence in women (OR 1.09, CI 1.04-1.12) but not men (OR 0.99, 95% CI 0.95-1.02). There were no other associations in heterosexuals. A history of HBV immunisation in homosexual men was recorded in 13/131 (9.9%) of new patients and 103/305 (33.8%; OR 4.63, CI 2.49-8.60) clinic reattenders. CONCLUSIONS: Although higher than a sample of blood donors, the prevalence of serological markers of HBV infection among heterosexuals was low, providing little support for extending HBV immunisation to all heterosexuals attending GUM clinics as a targeted strategy for control of HBV infection. Homosexual men remain at high risk of infection, but many are now being immunised. Efforts to improve compliance with existing vaccine policies in GUM clinics should be encouraged. 




Full Text

The Full Text of this article is available as a PDF (88.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alter M. J., Hadler S. C., Margolis H. S., Alexander W. J., Hu P. Y., Judson F. N., Mares A., Miller J. K., Moyer L. A. The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies. JAMA. 1990 Mar 2;263(9):1218–1222. [PubMed] [Google Scholar]
  2. Anderson N. A., Raafat A., Shwe K. H., Barbara J., Contreras M., Fraser I. D., Gunson H. H., Martlew V., Mijovic V., Goldíe D. J. U.K. multicentre study on blood donors for surrogate markers of non-A non-B hepatitis. Part I: Alanine transferase and anti-HBc testing. Transfus Med. 1992 Dec;2(4):301–310. doi: 10.1111/j.1365-3148.1992.tb00174.x. [DOI] [PubMed] [Google Scholar]
  3. Bhatti N., Gilson R. J., Beecham M., Williams P., Matthews M. P., Tedder R. S., Weller I. V. Failure to deliver hepatitis B vaccine: confessions from a genitourinary medicine clinic. BMJ. 1991 Jul 13;303(6794):97–101. doi: 10.1136/bmj.303.6794.97. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Boag F. Hepatitis B: heterosexual transmission and vaccination strategies. Int J STD AIDS. 1991 Sep-Oct;2(5):318–324. doi: 10.1177/095646249100200502. [DOI] [PubMed] [Google Scholar]
  5. Cowan F. M., Johnson A. M., Ashley R., Corey L., Mindel A. Antibody to herpes simplex virus type 2 as serological marker of sexual lifestyle in populations. BMJ. 1994 Nov 19;309(6965):1325–1329. doi: 10.1136/bmj.309.6965.1325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Evans B. G., Catchpole M. A., Heptonstall J., Mortimer J. Y., McCarrigle C. A., Nicoll A. G., Waight P., Gill O. N., Swan A. V. Sexually transmitted diseases and HIV-1 infection among homosexual men in England and Wales. BMJ. 1993 Feb 13;306(6875):426–428. doi: 10.1136/bmj.306.6875.426. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fenn P., Gray A., McGuire A. An economic evaluation of universal vaccination against hepatitis B virus. J Infect. 1996 May;32(3):197–204. doi: 10.1016/s0163-4453(96)80019-3. [DOI] [PubMed] [Google Scholar]
  8. Gilson R. J. Sexually transmitted hepatitis: a review. Genitourin Med. 1992 Apr;68(2):123–129. doi: 10.1136/sti.68.2.123. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Johnson A. M., Wadsworth J., Wellings K., Field J. Who goes to sexually transmitted disease clinics? Results from a national population survey. Genitourin Med. 1996 Jun;72(3):197–202. doi: 10.1136/sti.72.3.197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Mangtani P., Hall A. J., Normand C. E. Hepatitis B vaccination: the cost effectiveness of alternative strategies in England and Wales. J Epidemiol Community Health. 1995 Jun;49(3):238–244. doi: 10.1136/jech.49.3.238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Maynard J. E. Hepatitis B: global importance and need for control. Vaccine. 1990 Mar;8 (Suppl):S18–S23. doi: 10.1016/0264-410x(90)90209-5. [DOI] [PubMed] [Google Scholar]
  12. Polakoff S. Acute viral hepatitis B, reported to the Public Health Laboratory service. J Infect. 1990 Mar;20(2):163–168. doi: 10.1016/0163-4453(90)93522-t. [DOI] [PubMed] [Google Scholar]
  13. Tedder R. S., Cameron C. H., Wilson-Croome R., Howell D. R., Colgrove A., Barbara J. A. Contrasting patterns and frequency of antibodies to the surface, core, and e antigens of hepatitis B virus in blood donors and in homosexual patients. J Med Virol. 1981;6(4):323–332. doi: 10.1002/jmv.1890060407. [DOI] [PubMed] [Google Scholar]
  14. Van Damme P., Kane M., Meheus A. Integration of hepatitis B vaccination into national immunisation programmes. Viral Hepatitis Prevention Board. BMJ. 1997 Apr 5;314(7086):1033–1036. doi: 10.1136/bmj.314.7086.1033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Van Doornum G. J., Van Haastrecht H. J., Hooykaas C., Van den Hoek J. A., Van der Linden M. M., Coutinho R. A. Hepatitis B virus infection in a group of heterosexuals with multiple partners in Amsterdam, The Netherlands: implications for vaccination? J Med Virol. 1994 May;43(1):20–27. doi: 10.1002/jmv.1890430105. [DOI] [PubMed] [Google Scholar]
  16. Williams J. R., Nokes D. J., Anderson R. M. Targeted hepatitis B vaccination--a cost effective immunisation strategy for the UK? J Epidemiol Community Health. 1996 Dec;50(6):667–673. doi: 10.1136/jech.50.6.667. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Williams J. R., Nokes D. J., Medley G. F., Anderson R. M. The transmission dynamics of hepatitis B in the UK: a mathematical model for evaluating costs and effectiveness of immunization programmes. Epidemiol Infect. 1996 Feb;116(1):71–89. doi: 10.1017/s0950268800058970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. el-Dalil A. A., Jayaweera D. T., Walzman M., Radcliffe K. W., Richmond R., Wade A. A., Shahmanesh M. Hepatitis B markers in heterosexual patients attending two genitourinary medicine clinics in the West Midlands. Genitourin Med. 1997 Apr;73(2):127–130. doi: 10.1136/sti.73.2.127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. el-Dalil A., Radcliffe K. W., Bailey J., Richmond R. A., Wade A. A. A survey on hepatitis B vaccination policies in genitourinary medicine in UK and Ireland. Genitourin Med. 1995 Aug;71(4):251–253. doi: 10.1136/sti.71.4.251. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Sexually Transmitted Infections are provided here courtesy of BMJ Publishing Group

RESOURCES